UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2007

MEDICINOVA, INC. (Exact name of registrant as specified in its charter)

001-33185 (Commission File Number) 33-0927979 (IRS Employer Identification No.)

Delaware (State or other jurisdiction of incorporation)

> 4350 La Jolla Village Drive, Suite 950 San Diego, CA 92122 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Representatives of MediciNova, Inc. (the "Registrant") are scheduled to make a presentation at the 2007 UBS Global Life Sciences Conference on September 26, 2007 at 2:00 p.m. Eastern time. A copy of the slide presentation to be used by the Registrant at this conference is attached hereto as Exhibit 99.1.

The information in this Current Report, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for any purpose, including for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitDescription99.1Slide presentation of the Registrant

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

By: /s/ Shintaro Asako

Shintaro Asako Vice President and Chief Financial Officer

Dated: September 26, 2007

Exhibit 99.1 Description Slide presentation of the Registrant



Accelerating the global development and commercialization of innovative pharmaceuticals

September 2007



Safe Harbor Statement

This presentation contains forward-looking statements that involve risks and uncertainties. These forwardlooking statements include, but are not limited to, statements regarding our strategies and objectives, our plans for the development and commercialization of our product candidates, including development programs and clinical trials, our industry, our financial condition, liquidity and capital resources, the efficacy and potential benefits of our product candidates and other statements that are not historical facts. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would" or similar expressions. Actual results or events may differ materially from those expressed or implied in any forwardlooking statements due to various factors, including, without limitation, the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for our product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approvals, our reliance on third parties and the timing, cost and design of future clinical trials and research activities, the timing of our expected filings with the FDA, the failure to execute strategic plans or strategies successfully, our collaborations with third parties, intellectual property and contract rights, and the other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our annual report for the year ended December 31, 2006 and our subsequent periodic reports on Forms 10-Q and 8-K. You should not rely unduly on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update publicly or revise any forward-looking statements discussed in this presentation.

2

© MediciNova, Inc. 2007

(© Medicinova

Corporate Overview: MediciNova, Inc.

US-Based Pharmaceutical Development Company:

 Unique access to differentiated, high-value assets primarily from Japanese alliances

New Approaches to Treat

- Serious Medical Conditions:
 - Safe and potential disease modifying (neuroprotection) therapy for Multiple Scleros MediciNova Headquarters:
 - Easy intravenous formulation to treat Status Asthmaticus patients

Diverse Pipeline:

 Additional upside with six more compounds in development for various indications



San Diego, CA



© MediciNova, Inc. 2007

Business Model: Return On Investment

In-License:

 Product candidates ready to enter clinical or preclinical development

Proof-of-Concept Trials:

- Conduct Phase I and Phase II trials to prove safety bishi Pharma Corporation and efficacy of compound

4

Two Pathways Towards ROI

After Phase II:

 Continue internal development of compound towards commercialization

Seek partnership for compound

© MediciNova, Inc. 2007




KISSEI





A Focused Development Plan



MN-166 is a Next Generation Treatment for Multiple Sclerosis

In an oral delivery form, MN-166 provid high degree of safety with a broader (neuroprotective + anti-inflammatory efficacy profile than interferons.

Based on clinical and radiologic findings, MN-166 has the potential to modify disease progression by mitigating neuronal damage and to meet the need for a new MS therapy sought by the MS scientific community.



MN-166 Targets Chronic and Acute Aspects of Multiple Sclerosis


CHRONIC: (Current and Developing Treatments Are Not Neuroprotective)

Neuroprotecti@utcome:

- Attenuated % brain volume loss (- 0.79% vs. -1.2%)
- P-Value: 0.0352
- Potentially Slows Disease Progression via Neuroprotection
 - Stimulates Th2 cytokine production (IL-4, IL-10)
 - Stimulates neurotrofatitor release (NGF, GDNF, NT-4)
 - Cerebrovasodila(toiaPG) and/oadenosineceptors)



Chronic Efficacy Demonstrated: Effects on Brain Volume



MN-166 Targets Both Chronic and Acute Aspects of Multiple Sclerosis

ACUTE: (MN-166 Similar Acute Efficacy to Current and Developing Treatments)

Anti-inflammatory Outcomes:

- Pilot studies found reduced relapse rate andh2h1 cytokine shift
- Prolong time to relapse (> 1941)alue: 0.0438
- Increased % relapse-free (5p%)alue: 0.033
- Decreased T1-Gd lesion volume


Reduces Relapses via Inhibiting Inflammation

- Phosphodiesterase IV and Leukotriene inhibitor
- Inhibits nitric oxide and reactive oxygen species production
- Inhibits Th1 cytokine production (IFN-g, TNF-a, IL-1b, IL-6) ((

9

MEDICINOVA

Acute Efficacy Demonstrated: Time to First Relapse



Phase III endpoint for certain FDA-approved MS products

MEDIĈINOVA

© MediciNova, Inc. 2007

(MN-166 : Next Steps

- Complete Formulation Work on Once-Daily Dosing
 Anticipated completion date: November 2007
- Commence Relative Bioavailability Study (Ex-US)
 - Anticipated commencement date: Q1'08
- Announce Two-Year Phase II Results
 - Results expected: March 2008
- Submit US IND
 - Submission anticipated as early as March 2008

11

- Commence MTD Study
 - Anticipated commencement date: Q2'08
 - Results expected as early as Q4'08



MN-221: A New Approach to Treating Status Asthmaticus

Definition:


Long-lasting and severe asthma episode that is not responsive to initial bronchodilator or corticosteroid therapy

Market Opportunity:

- •~1.9 million emergency room visits in the U.S. each year*
- •~500,000 hospitalizations & ~4,000 deaths annually in the U.S.

Current Standard of Care:

- •Beta agonists, inhaled or nebuliz(adl patients)
- Corticosteroids, Vororal (66–77% of pts)



Phase IIa Study Ongoing; Results Expected in October 2007

*Source: National Center for Health Statistics/CDC

© MediciNova, Inc. 2007



Competitive Advantages of MN-221

- **1**. Proven mechanism of action (β_2 -adrenergic agonist)
- 2. Rapid, reliable IV delivery (vs. inhaled/nebulized)
- **3.** Safer (greater selectivity = fewer cardiovascular SE)

Human β-	Adrenergic	Receptor Sel	ectivity
Drug	Adrenoce	otor (IC ₅₀ , µM)	β ₂ -Adrenoceptor Selectivity
	β1	β ₂	$(IC_{50} \text{ for } \beta_1/IC_{50} \text{ for } \beta_2)$
MN-221	1.39	0.0224	62.1
Albuterol (Salbutamol)	5.63	1.56	3.61

Displacement of [3 H]-cvanopindolol or [3 H]-CGP12177 binding in membrane preparations expressing human cloned β_{1} - and β_{2} -adrenoceptors, respectively

MEDICINOVA

© MediciNova, Inc. 2007

(MN-221: Next Steps


- Announce Phase IIa results in October 2007
- Commence Phase IIb study to test efficacy of MN-221 in Status Asthmaticus patients in the emergency room
 - Anticipated commencement date: Q2'08
 - Results expected as early as Q2'09
- Commence second Phase IIa study for Extended Dosing (4

14

- Hour Infusion)
 - Anticipated commencement date: Q1'08
 - Results expected as early as Q3'08



Commercially-Attractive Diversified Portfolio



© MediciNova, Inc. 2007



ONear-Term Clinical Milestones

MN-221	 Phase II Status Asthmaticus results expected October 2007 	
MN-305	 Phase II Insomnia results expected October 2007 	
MN-166	 Two-Year Phase II results expected March 2008 	

© MediciNova, Inc. 2007

16

(O MEDICINOVA

(ONear-Term Licensing Opportunities

• MN-305: For Insomnia

- Phase II results expected October 2007

MN-166: For Multiple Sclerosis

- Positive one-year Phase II results

announced March 2007

• MN-001: For Asthma



 Once-daily formulation work ongoing; completion of new formulation expected as early as Q2'08

17

New composition of matter patent granted; patent protection through 2023





Dual Listing:

- MNOV (NasdaqGM), December 2006

- 4875 (Osaka (Hercules), February 2005

- Cash: \$85.9M as of 6/30/07
- Expected Cash Balance: ~\$65M as of 12/31/07

18

- Market cap as of 9/20/07: ~\$84.4M
- Shares outstanding: 11.6M





Management Team with Global Experience

-	Leadership	Years Experience	Background
	Yuichi Iwaki, MD, PhD CEO & President	31	Prof. USC, Pitt; Advisor to JAFCO, Tanabe Director, Avigen, Inc.
	Richard Gammans, PhD, MBA Chief Development Officer	30	Incara, Indevus, BMS
	Kenneth W. Locke, PhD Chief Scientific Officer	23	Tanabe Research Laboratories USA, Indevus, Hoechst
	Shintaro Asako, CPA Chief Financial Officer	8	KPMG USA (Audit), Arthur Andersen USA
	Masatsune Okajima, CMA VP, Head of Japanese Office	15	Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank

© MediciNova, Inc. 2007



OInvestment Highlights

Unique In-Licensing Approach

 Access to Differentiated, High-Value, Assets from Primarily Japanese Alliances

Focused Internal Development Plan

- MN-166: Neuroprotective Treatment for Multiple Sclerosis
- MN-221: IV Formulation for Status Asthmaticus

Broad Pipeline

 Multiple Opportunities for Value Creation through Establishment of Partnerships

20

